Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director · Interim CEO & General Counsel | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 602,085 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 15,626 · Balance 602,085 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 595,447 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 6,638 · Balance 595,447 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 93,756 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 15,626 · Balance 93,756 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · derivative · entry 5 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,504 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 19,913 | $10.85 | $216,056.05 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · nonDerivative · entry 4 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,262 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · nonDerivative · entry 3 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,426 | $10.85 | $48,022.10 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,300 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097491 · tm2423453-4_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Director · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-080619 · tm2419709-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,669 Underlying: Common stock · 20,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $8.68 | $76,826.68 |
DisclosureSEC source: 0001104659-24-080619 · tm2419709-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,309 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-080619 · tm2419709-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-068771 · tm2416581-1_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,921 Underlying: Common stock · 10,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,426 | $8.37 | $37,045.62 |
DisclosureSEC source: 0001104659-24-068771 · tm2416581-1_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,325 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-068771 · tm2416581-1_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:08 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048429 · tm2412101-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,504 Underlying: Common stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:08 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $11.89 | $105,238.39 |
DisclosureSEC source: 0001104659-24-048429 · tm2412101-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,334 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:08 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048429 · tm2412101-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:19 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 41,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031576 · tm248073-2_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,338 Underlying: Common stock · 41,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:19 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 11,449 | $16.96 | $194,175.04 |
DisclosureSEC source: 0001104659-24-031576 · tm248073-2_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,351 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:19 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 41,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031576 · tm248073-2_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031113 · tm248017-9_4seq1.xml · derivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common stock · 93,750 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:56 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031113 · tm248017-9_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock · 500,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:09 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004866 · tm243610-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,338 Underlying: Common stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:09 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,530 | $8.37 | $54,656.10 |
DisclosureSEC source: 0001104659-24-004866 · tm243610-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,138 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:09 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004866 · tm243610-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109942 · tm2328751-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,172 Underlying: Common stock · 20,835 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in five equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in five equal quarterly installments. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $3.57 | $31,598.07 |
DisclosureSEC source: 0001104659-23-109942 · tm2328751-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,834 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109942 · tm2328751-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:22 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081715 · tm2321428-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,007 Underlying: Common stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in six equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in six equal quarterly installments. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:22 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $7.76 | $68,683.76 |
DisclosureSEC source: 0001104659-23-081715 · tm2321428-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,850 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:22 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081715 · tm2321428-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046844 · tm2313085-3_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,841 Underlying: Common stock · 20,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in seven equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in seven equal quarterly installments. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 8,851 | $5.64 | $49,919.64 |
DisclosureSEC source: 0001104659-23-046844 · tm2313085-3_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,867 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:50 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 20,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046844 · tm2313085-3_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: 20,834 of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022 vested and settled on April 14, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:27 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001104659-23-029101 · tm238642-4_4seq1.xml · derivative · entry 2 Vogt Frederick G · CIK 0001719678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-03-02 F3 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:27 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-029101 · tm238642-4_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 83,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-005045 · tm233853d1_4seq1.xml · derivative · entry 3 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,675 Underlying: Common stock · 83,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in eight equal quarterly installments over the next two years. F5 · derivative.expiration_date: The remaining RSUs will vest in eight equal quarterly installments over the next two years. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 36,441 | $6.43 | $234,315.63 |
DisclosureSEC source: 0001104659-23-005045 · tm233853d1_4seq1.xml · nonDerivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,884 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:51 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 83,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-005045 · tm233853d1_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: One-third of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022, vested on January 14, 2023. The vested RSUs were settled on January 17, 2023. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 02:46 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 1,000 | $5.98 | $5,980.00 |
DisclosureSEC source: 0001104659-22-122556 · tm2231429-2_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 1,000 | $6.44 | $6,440.00 |
DisclosureSEC source: 0001104659-22-067758 · tm2217576d2_4seq1.xml · nonDerivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005599 · tm223806-4_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 73,900 | $0.00 Strike: $23.87 | $0.00 |
DisclosureSEC source: 0001104659-21-082064 · tm2119923-1_4seq1.xml · derivative · entry 2 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,900 Underlying: Common Stock · 73,900 shares Expires 2031-06-14 F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-half of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest on December 31, 2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $23.87 | $0.00 |
DisclosureSEC source: 0001104659-21-082064 · tm2119923-1_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · Interim CEO & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $46.26 | $0.00 |
DisclosureSEC source: 0001104659-21-001571 · tm211898-1_4seq1.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 02:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001104659-20-002088 · tm201473d3_4.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 150,000 shares shall vest on the one-year anniversary of January 3, 2020; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of January 3, 2020. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $11.26 | $0.00 |
DisclosureSEC source: 0001144204-19-012580 · tv515608_4.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common stock · 200,000 shares Expires 2019-03-04 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 200,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019. Read SEC document |
| December 29, 2017 Filed Jan 8, 2018 18:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 37,400 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001250853-18-000014 · primary_doc.xml · derivative · entry 1 Vogt Frederick G · CIK 0001719678 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,400 Underlying: Common Stock · 37,400 shares Expires 2027-12-28 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 37,400 shares shall vest on the one-year anniversary of December 29, 2017; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of December 29, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.